Memorial Sloan-Kettering Cancer Center, which has long been active as a major clinical research center, took its first step into the formal business of biotech, forming an as-yet unnamed startup company with Sequana Therapeutics Inc.

After looking at several genomics companies, Sloan-Kettering approached SQNA to form a joint venture, according to SQNA President and CEO Kevin Kinsella.